Dual Molecules Targeting 5-HT6 and GABA-A Receptors as a New Approach to Combat Depression Associated with Neuroinflammation

While monoaminergic deficits are evident in all depressed patients, nonresponders are characterized by impaired GABA-ergic signaling and the simultaneous presence of the inflammatory component. Pharmacological agents able to curb pathological immune responses and modulate ineffective GABA-ergic neurotransmission are thought to improve therapeutic outcomes in the treatment-resistant subgroup of depressed patients. Here, we report on a set of dually acting molecules designed to simultaneously modulate GABA-A and 5-HT6 receptor activity. The serotonin 5-HT6 receptor was chosen as a complementary molecular target, due to its promising antidepressant-like activities reported in animal studies. Within the study we identified that lead molecule 16 showed a desirable receptor profile and physicochemical properties. In pharmacological studies, 16 was able to reduce the secretion of proinflammatory cytokines and decrease oxidative stress markers. In animal studies, 16 exerted antidepressant-like activity deriving from a synergic interplay between 5-HT6 and GABA-A receptors. Altogether, the presented findings point to hybrid 16 as an interesting tool that interacts with pharmacologically relevant targets, matching the pathological dysfunction of depression associated with neuroinflammation.

[1]  T. Karcz,et al.  Hybrid molecules combining GABA-A and serotonin 5-HT6 receptors activity designed to tackle neuroinflammation associated with depression. , 2022, European journal of medicinal chemistry.

[2]  David E. Gloriam,et al.  GPCRs steer Gi and Gs selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors. , 2022, Molecular cell.

[3]  M. Kołaczkowski,et al.  Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia , 2021, Journal of medicinal chemistry.

[4]  J. Handzlik,et al.  Chemical update on the potential for serotonin 5-HT6 and 5-HT7 receptor agents in the treatment of Alzheimer's disease. , 2021, Bioorganic & medicinal chemistry letters.

[5]  Ahmet Avci,et al.  Potential of nafimidone derivatives against co‐morbidities of epilepsy: In vitro, in vivo, and in silico investigations , 2021, Drug development research.

[6]  P. Legendre,et al.  Electrophysiology of ionotropic GABA receptors , 2021, Cellular and Molecular Life Sciences.

[7]  Qidi Ai,et al.  The Anti-Neuroinflammatory Effect of Fuzi and Ganjiang Extraction on LPS-Induced BV2 Microglia and Its Intervention Function on Depression-Like Behavior of Cancer-Related Fatigue Model Mice , 2021, Frontiers in Pharmacology.

[8]  N. Jaafari,et al.  On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos? , 2021, Journal of neuroinflammation.

[9]  T. Wilcox,et al.  Targeting nitric oxide production in microglia with novel imidazodiazepines for non-sedative pain treatment. , 2020, ACS chemical neuroscience.

[10]  Weifeng Yu,et al.  Electrophysiological Studies of GABAA Receptors Using QPatch II, the Next Generation of Automated Patch‐Clamp Instruments , 2020, Current protocols in pharmacology.

[11]  P. Moraes-Vieira,et al.  Using flow cytometry for mitochondrial assays , 2020, MethodsX.

[12]  M. Kołaczkowski,et al.  Anti‐Alzheimer's multitarget‐directed ligands with serotonin 5‐HT6 antagonist, butyrylcholinesterase inhibitory, and antioxidant activity , 2019, Archiv der Pharmazie.

[13]  R. Duman,et al.  Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions , 2019, Front. Cell. Neurosci..

[14]  D. Goldsmith,et al.  Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder , 2018, Psychoneuroendocrinology.

[15]  M. Maes,et al.  Lipid Peroxidation and Immune Biomarkers Are Associated with Major Depression and Its Phenotypes, Including Treatment-Resistant Depression and Melancholia , 2017, Neurotoxicity Research.

[16]  W. Drevets,et al.  The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman’s disease , 2017, Brain, Behavior, and Immunity.

[17]  S. Gilman,et al.  Sex differences in recent first-onset depression in an epidemiological sample of adolescents , 2017, Translational Psychiatry.

[18]  T. Karcz,et al.  3-Aminomethyl Derivatives of 2-Phenylimidazo[1,2-a]-pyridine as Positive Allosteric Modulators of GABAA Receptor with Potential Antipsychotic Activity. , 2017, ACS Chemical Neuroscience.

[19]  W. Ren,et al.  The immunological function of GABAergic system. , 2017, Frontiers in bioscience.

[20]  T. Karcz,et al.  Design, synthesis, and biological evaluation of fluorinated imidazo[1,2-a]pyridine derivatives with potential antipsychotic activity. , 2016, European journal of medicinal chemistry.

[21]  M. Kołaczkowski,et al.  Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats , 2016, Naunyn-Schmiedeberg's Archives of Pharmacology.

[22]  M. Kołaczkowski,et al.  Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. , 2015, European journal of medicinal chemistry.

[23]  Motty Franko,et al.  The forced swim test as a model of depressive-like behavior. , 2015, Journal of visualized experiments : JoVE.

[24]  Marcin Feder,et al.  Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening , 2013, J. Chem. Inf. Model..

[25]  C. Aw,et al.  In vivo 5-HT6 receptor occupancy by antipsychotic drugs in the rat brain , 2011, Neuroscience Letters.

[26]  M. Berk,et al.  A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[27]  B Luscher,et al.  The GABAergic deficit hypothesis of major depressive disorder , 2011, Molecular Psychiatry.

[28]  P. Mcgeer,et al.  Astrocytes are GABAergic cells that modulate microglial activity , 2011, Glia.

[29]  G. Homanics,et al.  Prototypic GABAA Receptor Agonist Muscimol Acts Preferentially Through Forebrain High-Affinity Binding Sites , 2010, Neuropsychopharmacology.

[30]  Dennis S. Charney,et al.  Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder , 2009, Biological Psychiatry.

[31]  H. Kettenmann,et al.  GABAergic activities enhance macrophage inflammatory protein‐1α release from microglia (brain macrophages) in postnatal mouse brain , 2009, The Journal of physiology.

[32]  P. Balimane,et al.  A Novel Design of Artificial Membrane for Improving the PAMPA Model , 2008, Pharmaceutical Research.

[33]  W. Klaffke,et al.  Comparison of In Vitro Assays of Cellular Toxicity in the Human Hepatic Cell Line HepG2 , 2006, Journal of biomolecular screening.

[34]  R. Blakely,et al.  The Proinflammatory Cytokines Interleukin-1beta and Tumor Necrosis Factor-Alpha Activate Serotonin Transporters , 2006, Neuropsychopharmacology.

[35]  A. Nussler,et al.  Fluorometric measurement of nitrite/nitrate by 2,3-diaminonaphthalene , 2006, Nature Protocols.

[36]  L. Di,et al.  Development and application of high throughput plasma stability assay for drug discovery. , 2005, International journal of pharmaceutics.

[37]  D. A. Hartman Determination of the stability of drugs in plasma. , 2003, Current protocols in pharmacology.

[38]  J. Hescheler,et al.  Activation of p90RSK and growth stimulation of multicellular tumor spheroids are dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  Fahmeed Hyder,et al.  Reduced Cortical γ-Aminobutyric Acid Levels in Depressed Patients Determined by Proton Magnetic Resonance Spectroscopy , 1999 .

[40]  E. Bosmans,et al.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. , 1997, Cytokine.

[41]  R. Porsolt,et al.  Behavioural despair in rats: a new model sensitive to antidepressant treatments. , 1978, European journal of pharmacology.